Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
miR-15 and miR-16 induce apoptosis by targeting BCL2
2005 Standout
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
2008
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Prevalence of pain in patients with breast cancer post-treatment: A systematic review
2018
Cancer treatment and survivorship statistics, 2022
2022 Standout
Breast cancer statistics, 2019
2019 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes
1997
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
2004
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
2004
SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)
2005
A Quantitative Nitroblue Tetrazolium Assay for Determining Intracellular Superoxide Anion Production in Phagocytic Cells
2006
Ayurveda and Traditional Chinese Medicine: A Comparative Overview
2005 Standout
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
2006
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Treatment of Non-Hodgkin's Lymphoma
1993
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
2010
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
2002 Standout
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
2005
RB and cell cycle progression
2006 Standout
Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A
2000
Targeting multidrug resistance in cancer
2006 Standout
Richter syndrome
2004
Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatment
2006
Rituximab therapy for childhood-onset systemic lupus erythematosus
2006
Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma
2009
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Systemic Lupus Erythematosus
2011 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
2006
microRNAs as oncogenes and tumor suppressors
2006 Standout
MicroRNA signatures in human cancers
2006 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia:
2004
Idarubicin
1991
Heavy Metal Content of Ayurvedic Herbal Medicine Products
2004
HEPATOSPLENIC CANDIDIASIS
2000
Mitoxantrone
1996
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
2003
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL
2004
Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids
2006
Heavy metals and living systems: An overview
2011 Standout
Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies
2004
B-cell depletion in the treatment of mixed cryoglobulinemia
2007
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Bendamustine: Rebirth of an Old Drug
2009
IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
1998
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
The effect of oligopeptides on the C3b receptor-mediated functions of rat macrophages
1983
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Invasive Candidiasis
2015 Standout
Retinoblastoma protein family in cell cycle and cancer: A review
1996
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies
2016
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Cell cycle deregulation in B-cell lymphomas
2003
Cancer treatment and survivorship statistics, 2019
2019 Standout
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20
2003
Superoxide Ion: Generation and Chemical Implications
2016 Standout
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
2008
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
2009
2016 Standout
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
2018
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Works of H. Köppler being referenced
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
2014
Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: Treatment results and prognostic factor analysis in a multi-centre trial
1994
CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study
1989
Ultrasound evaluation of hepatic and splenic microabscesses in the immunocompromised patient: Sonographic patterns, differential diagnosis, and follow‐up
1994
Breast Cancer Morbidity
2014
Chronische Bleivergiftung durch ayurvedische Heilpillen
2003
Bendamustine Mitoxantrone and Rituximab (BMR): A New Effective Regimen for Refractory or Relapsed Indolent Lymphomas
2002
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
2007
Bendamustine Plus Mitoxantrone—A New Effective Treatment for Advanced Chronic Lymphocytic Leukaemia: Results of a Phase I/II Study
2004
Induction of Complete Haematological Remission After Monotherapy with AntLCD20 Monoclonal Antibody (RITUXIMAB) in a Patient with Alkylating Agent Resistant Waldenstrom's Macroglobulinaemia
1999
High-Dose Versus Intermediate Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age Adjusted Randomized Comparison
1993
The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab
2000
Age Related Randomized Comparison of Sequentially Applied High-Dose versus Intermediate Dose Cytosine Arabinoside in Combination with Mitoxantrone (S-HAM) in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Study Design and Preliminary Results
1989
Sequential versus alternating chemotherapy for high grade non‐hodgkin's lymphomas: A randomized multicentre trial
1991
Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas.
1994
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
2003
A Modified Spectrophotometric Test for Nitroblue-Tetrazolium Reduction of Granulocytes and Monocytes and its Application for Testing Inhibition of Monocytes by Serum Components in Tumor Patients
1980
High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison
1992
Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study
2004
Cleavage of IgG by Elastase-Like Protease (ELP) of Human Polymorphonuclear Leukocytes (PMN): Isolation and Characterization of Fab and Fc Fragments and Low-Molecular-Weight Peptides Stimulation of Granulocyte Function by ELP-Derived Fab and Fc Fragments
1982